Close Menu

NEW YORK — Medidata, a developer of life science data management and analysis software, said on Friday that it has partnered with non-profit Project ALS to study amyotrophic lateral sclerosis (ALS) using the company's machine learning-based Rave Omics biomarker discovery platform.

According to Medidata, Rave Omics is designed to capture and analyze genomic, proteomic, transcriptomic and other omic data during clinical studies in order to identify biomarkers that can be used for patient stratification. Rave Omics is managed by Medidata subsidiary Acorn AI.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.